Glenmark launches pulmonary fibrosis drug NINDANIB in India

In a recently published INBUILD trial, Nintedanib showed significantly lower annual rate of decline in FVC (Forced Vital Capacity) – a measure of lung health – with various progressive fibrosing interstitial lung diseases. Moreover, two clinical trials are being rolled out for to study the efficacy and safety of Nintedanib as a treatment of SARS-COV2 induced pulmonary fibrosis in Moderate to Severe COVID-19 patients.

"With limited treatment options available, interstitial lung diseases pose a significant treatment challenge in India. The high price of newer treatments and the pill burden of existing options only add to poor patient adherence. By introducing NINDANIB, we hope to substantially reduce both the pill and cost burden for patients in India," said Mr. Alok Malik, Group Vice President & Business Head, India Formulations.

He added, "Glenmark continues to invent and innovate healthcare solutions that meet specific and often hard-to-address needs of patients in India and the world."

Pulmonary fibrosis (PF) is a respiratory condition characterized by the thickening and/or scarring of the lungs. This makes it difficult for oxygen to pass through the air sacs and into the bloodstream, causing symptoms such as shortness of breath and dry cough. The average survival rate in patients with IPF is poor, with only 20 to 30 percent of people surviving at least five years after diagnosis. The most frequent cause of death is respiratory failure. IPF typically affects men over the age of 65 in India, and most people with IPF live only three to five years post diagnosis, if left untreated.

Read also: Glenmark gets USFDA approval for Dimethyl Fumarate Delayed-Release Capsules